Suppr超能文献

植物生产的RBD和基于鸡尾酒的候选疫苗对SARS-CoV-2高度有效,与其新出现的变种无关。

Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants.

作者信息

Mamedov Tarlan, Yuksel Damla, Gurbuzaslan Irem, Ilgin Merve, Gulec Burcu, Mammadova Gulshan, Ozdarendeli Aykut, Pavel Shaikh Terkis Islam, Yetiskin Hazel, Kaplan Busra, Uygut Muhammet Ali, Hasanova Gulnara

机构信息

Department of Agricultural Biotechnology, Akdeniz University, Antalya, Türkiye.

Institute of Molecular Biology and Biotechnologies, Ministry of Science and Education, Republic of Azerbaijan, Baku, Azerbaijan.

出版信息

Front Plant Sci. 2023 Aug 2;14:1202570. doi: 10.3389/fpls.2023.1202570. eCollection 2023.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel and highly pathogenic coronavirus that caused an outbreak in Wuhan City, China, in 2019 and then spread rapidly throughout the world. Although several coronavirus disease 2019 (COVID-19) vaccines are currently available for mass immunization, they are less effective against emerging SARS-CoV-2 variants, especially the Omicron (B.1.1.529). Recently, we successfully produced receptor-binding domain (RBD) variants of the spike (S) protein of SARS-CoV-2 and an antigen cocktail in , which are highly produced in plants and elicited high-titer antibodies with potent neutralizing activity against SARS-CoV-2. In this study, based on neutralization ability, we demonstrate that plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants. These data demonstrate that plant-produced RBD and cocktail-based proteins are the most promising vaccine candidates and may protect against Delta and Omicron-mediated COVID-19. This is the first report describing vaccines against SARS-CoV-2, which demonstrate significant activities against Delta and Omicron variants.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种新型高致病性冠状病毒,于2019年在中国武汉市引发疫情,随后迅速蔓延至全球。尽管目前有几种2019冠状病毒病(COVID-19)疫苗可用于大规模免疫接种,但它们对新出现的SARS-CoV-2变体效果较差,尤其是奥密克戎(B.1.1.529)变体。最近,我们成功在植物中生产了SARS-CoV-2刺突(S)蛋白的受体结合域(RBD)变体和一种抗原混合物,它们在植物中大量产生,并引发了对SARS-CoV-2具有强大中和活性的高滴度抗体。在本研究中,基于中和能力,我们证明植物产生的RBD和基于混合物的候选疫苗对SARS-CoV-2高度有效,与其新出现的变体无关。这些数据表明,植物产生的RBD和基于混合物的蛋白质是最有前途的候选疫苗,可能预防由德尔塔和奥密克戎介导的COVID-19。这是第一份描述针对SARS-CoV-2疫苗的报告,该疫苗对德尔塔和奥密克戎变体显示出显著活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bd2/10433747/55573c6c1fd9/fpls-14-1202570-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验